Global biotechnology company NodThera is developing a new class of potent and selective small-molecule NLRP3 inhibitors for the treatment of diseases driven by chronic inflammation, such as ...

BioAge is developing structurally distinct APJ agonists in its pipeline ... BioAge is developing its novel, proprietary class of NLRP3 inhibitors, which have distinctive structural and biological ...

BMS will gain rights to IFM’s preclinical stimulator of interferon genes (STING) and NLRP3 agonist drugs, which aim to enhance the innate immune response against cancer. It will pay $300 million ...

Two months after going public, BioAge stopped a phase 2 trial of its oral apelin receptor agonist azelaprag ... BioAge’s NLRP3 inhibitor has become the biotech’s most advanced prospect.

BioAge is developing structurally distinct APJ agonists in its pipeline, with the goal of nominating a development candidate by the end of 2025. • Nomination of NLRP3 inhibitor BGE-102 as a ...

Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.

BioAge is developing structurally distinct APJ agonists in its pipeline, with the goal of nominating a development candidate by the end of 2025. • Nomination of NLRP3 inhibitor BGE-102 as a ...